JP2005517433A5 - - Google Patents

Download PDF

Info

Publication number
JP2005517433A5
JP2005517433A5 JP2003569790A JP2003569790A JP2005517433A5 JP 2005517433 A5 JP2005517433 A5 JP 2005517433A5 JP 2003569790 A JP2003569790 A JP 2003569790A JP 2003569790 A JP2003569790 A JP 2003569790A JP 2005517433 A5 JP2005517433 A5 JP 2005517433A5
Authority
JP
Japan
Prior art keywords
sina molecule
nucleotide
nucleotides
fragment
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003569790A
Other languages
Japanese (ja)
Other versions
JP2005517433A (en
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/004741 external-priority patent/WO2003070897A2/en
Publication of JP2005517433A publication Critical patent/JP2005517433A/en
Publication of JP2005517433A5 publication Critical patent/JP2005517433A5/ja
Pending legal-status Critical Current

Links

Claims (34)

ＲＮＡ干渉（ＲＮＡｉ）により腫瘍壊死因子（ＴＮＦ）ＲＮＡの切断を指示する、化学的に合成された二本鎖短干渉核酸（ｓｉＮＡ）分子であって，本質的に第１の核酸鎖と第２の核酸鎖からなり，ここで，
ａ．第１の核酸鎖は第２の鎖に対して相補性を有しており；
ｂ．前記ｓｉＮＡ分子の各鎖は１９−２９ヌクレオチドの長さであり；そして
ｃ．前記ｓｉＮＡ分子はセンス鎖の５’末端および／または３’末端およびアンチセンス鎖の３’末端に少なくとも１つの化学的に修飾されたヌクレオチドまたは非ヌクレオチドを含む，
ことを特徴とするｓｉＮＡ分子。 A chemically synthesized double stranded short interfering nucleic acid (siNA) molecule that directs cleavage of tumor necrosis factor (TNF) RNA by RNA interference (RNAi), essentially consisting of a first nucleic acid strand and a second nucleic acid strand Of nucleic acid strands, where
a. The first nucleic acid strand is complementary to the second strand;
b. Each strand of the siNA molecule is 19-29 nucleotides in length; and c. The siNA molecule comprises at least one chemically modified nucleotide or non-nucleotide at the 5 ′ end and / or the 3 ′ end of the sense strand and the 3 ′ end of the antisense strand;
SiNA molecules characterized in that. 前記ｓｉＮＡ分子がリボヌクレオチドを含まない，請求項１記載のｓｉＮＡ分子。 2. The siNA molecule of claim 1, wherein the siNA molecule does not contain ribonucleotides. 前記ｓｉＮＡ分子が１またはそれ以上のリボヌクレオチドを含む，請求項１記載のｓｉＮＡ分子。 The siNA molecule of claim 1, wherein the siNA molecule comprises one or more ribonucleotides. 前記化学的に修飾されたヌクレオチドが２’−デオキシヌクレオチドを含む，請求項１記載のｓｉＮＡ分子。 The siNA molecule of claim 1, wherein the chemically modified nucleotide comprises a 2'-deoxy nucleotide. 前記化学的に修飾されたヌクレオチドが２’−デオキシ−２’−フルオロヌクレオチドを含む，請求項１記載のｓｉＮＡ分子。 The siNA molecule of claim 1, wherein the chemically modified nucleotide comprises a 2'-deoxy-2'-fluoro nucleotide. 前記化学的に修飾されたヌクレオチドが２’−Ｏ−メチルヌクレオチドを含む，請求項１記載のｓｉＮＡ分子。 The siNA molecule of claim 1, wherein the chemically modified nucleotide comprises a 2'-O-methyl nucleotide. 前記化学的に修飾されたヌクレオチドがホスホロチオエートヌクレオチド間結合を含む，請求項１記載のｓｉＮＡ分子。 The siNA molecule of claim 1, wherein the chemically modified nucleotide comprises a phosphorothioate internucleotide linkage. 前記非ヌクレオチドが無塩基成分を含む，請求項１記載のｓｉＮＡ分子。 The siNA molecule of claim 1, wherein the non-nucleotide comprises an abasic component. 前記無塩基成分が反転デオキシ無塩基成分を含む，請求項８記載のｓｉＮＡ分子。 9. The siNA molecule of claim 8, wherein the abasic component comprises an inverted deoxy abasic component. 前記非ヌクレオチドがグリセリル成分を含む，請求項１記載のｓｉＮＡ分子。 The siNA molecule of claim 1, wherein the non-nucleotide comprises a glyceryl moiety. ｓｉＮＡ分子の各鎖が１９−２５ヌクレオチドを含み，各鎖が他方の鎖のヌクレオチドと相補的な少なくとも１９ヌクレオチドを含む，請求項１記載のｓｉＮＡ分子。 2. The siNA molecule of claim 1, wherein each strand of the siNA molecule comprises 19-25 nucleotides and each strand comprises at least 19 nucleotides complementary to the nucleotides of the other strand. 前記ｓｉＮＡ分子が２つの別々のオリゴヌクレオチドフラグメントから組み立てられており，一方のフラグメントは前記ｓｉＮＡ分子のセンス領域を含み，第２のフラグメントは前記ｓｉＮＡ分子のアンチセンス領域を含む，請求項１記載のｓｉＮＡ分子。 2. The siNA molecule is assembled from two separate oligonucleotide fragments, one fragment comprising the sense region of the siNA molecule and a second fragment comprising the antisense region of the siNA molecule. siNA molecule. 前記センス領域がリンカー分子を介してアンチセンス領域に連結されている，請求項１記載のｓｉＮＡ分子。 The siNA molecule of claim 1, wherein the sense region is linked to an antisense region via a linker molecule. 前記リンカー分子がポリヌクレオチドリンカーである，請求項１３記載のｓｉＮＡ分子。 14. The siNA molecule of claim 13, wherein the linker molecule is a polynucleotide linker. 前記リンカー分子が非ヌクレオチドリンカーである，請求項１３記載のｓｉＮＡ分子。 14. The siNA molecule of claim 13, wherein the linker molecule is a non-nucleotide linker. センス領域中のピリミジンヌクレオチドが２’−Ｏ−メチルピリミジンヌクレオチドである，請求項１記載のｓｉＮＡ分子。 The siNA molecule of claim 1, wherein the pyrimidine nucleotides in the sense region are 2'-O-methylpyrimidine nucleotides. センス領域中のプリンヌクレオチドが２’−デオキシプリンヌクレオチドである，請求項１記載のｓｉＮＡ分子。 The siNA molecule of claim 1, wherein the purine nucleotide in the sense region is a 2'-deoxy purine nucleotide. センス領域中に存在するピリミジンヌクレオチドが２’−デオキシ−２’−フルオロピリミジンヌクレオチドである，請求項１記載のｓｉＮＡ分子。 The siNA molecule of claim 1, wherein the pyrimidine nucleotide present in the sense region is a 2'-deoxy-2'-fluoropyrimidine nucleotide. 前記センス領域を含むフラグメントが，前記センス領域を含むフラグメントの５’末端，３’末端，または５’末端および３’末端の両方に末端キャップ成分を含む，請求項１２記載のｓｉＮＡ分子。 13. The siNA molecule of claim 12, wherein the fragment comprising the sense region comprises an end cap component at the 5 'end, 3' end, or both the 5 'end and the 3' end of the fragment comprising the sense region. 前記末端キャップ成分が反転デオキシ無塩基成分である，請求項１９記載のｓｉＮＡ分子。 20. The siNA molecule of claim 19, wherein the end cap component is an inverted deoxy abasic component. 前記アンチセンス領域のピリミジンヌクレオチドが２’−デオキシ−２’−フルオロピリミジンヌクレオチドである，請求項１記載のｓｉＮＡ分子。 The siNA molecule of claim 1, wherein the pyrimidine nucleotides of the antisense region are 2'-deoxy-2'-fluoropyrimidine nucleotides. 前記アンチセンス領域のプリンヌクレオチドが２’−Ｏ−メチルプリンヌクレオチドである，請求項１記載のｓｉＮＡ分子。 The siNA molecule according to claim 1, wherein the purine nucleotide in the antisense region is a 2'-O-methylpurine nucleotide. 前記アンチセンス領域中に存在するプリンヌクレオチドが２’−デオキシ−プリンヌクレオチドを含む，請求項１記載のｓｉＮＡ分子。 The siNA molecule of claim 1, wherein the purine nucleotide present in the antisense region comprises a 2'-deoxy-purine nucleotide. 前記アンチセンス領域が前記アンチセンス領域の３’末端にホスホロチオエートヌクレオチド間結合を含む，請求項２１記載のｓｉＮＡ分子。 22. The siNA molecule of claim 21, wherein the antisense region comprises a phosphorothioate internucleotide linkage at the 3 'end of the antisense region. 前記アンチセンス領域が前記アンチセンス領域の３’末端にグリセリル修飾を含む，請求項１記載のｓｉＮＡ分子。 The siNA molecule of claim 1, wherein the antisense region comprises a glyceryl modification at the 3 'end of the antisense region. 前記ｓｉＮＡ分子の２つのフラグメントのそれぞれが２１ヌクレオチドを含む，請求項１２記載のｓｉＮＡ分子。 13. The siNA molecule of claim 12, wherein each of the two fragments of the siNA molecule comprises 21 nucleotides. ｓｉＮＡ分子の各フラグメントの約１９ヌクレオチドはｓｉＮＡ分子の他方のフラグメントの相補的ヌクレオチドと塩基対形成し，ｓｉＮＡ分子の各フラグメントの少なくとも２つの３’末端ヌクレオチドはｓｉＮＡ分子の他方のフラグメントのヌクレオチドと塩基対形成しない，請求項２６記載のｓｉＮＡ分子。 Approximately 19 nucleotides of each fragment of the siNA molecule base pair with the complementary nucleotide of the other fragment of the siNA molecule, and at least two 3 ′ terminal nucleotides of each fragment of the siNA molecule are bases and nucleotides of the other fragment of the siNA molecule. 27. The siNA molecule of claim 26, which does not pair. ｓｉＮＡ分子の各フラグメントの２つの３’末端ヌクレオチドのそれぞれが２’−デオキシ−ピリミジンである，請求項２７記載のｓｉＮＡ分子。 28. The siNA molecule of claim 27, wherein each of the two 3 'terminal nucleotides of each fragment of the siNA molecule is 2'-deoxy-pyrimidine. 前記２’−デオキシ−ピリミジンが２’−デオキシ−チミジンである，請求項２８記載のｓｉＮＡ分子。 29. The siNA molecule of claim 28, wherein the 2'-deoxy-pyrimidine is 2'-deoxy-thymidine. ｓｉＮＡ分子の各フラグメントの２１ヌクレオチドのすべてがｓｉＮＡ分子の他方のフラグメントの相補的ヌクレオチドと塩基対形成する，請求項２６記載のｓｉＮＡ分子。 27. The siNA molecule of claim 26, wherein all 21 nucleotides of each fragment of the siNA molecule base pair with a complementary nucleotide of the other fragment of the siNA molecule. アンチセンス領域の１９ヌクレオチドがＴＮＦ遺伝子またはその一部によりコードされるＲＮＡのヌクレオチド配列と塩基対形成する，請求項２６記載のｓｉＮＡ分子。 27. The siNA molecule of claim 26, wherein the 19 nucleotides of the antisense region are base-paired with the nucleotide sequence of RNA encoded by the TNF gene or part thereof. アンチセンス領域の２１ヌクレオチドがＴＮＦ遺伝子またはその一部によりコードされるＲＮＡのヌクレオチド配列と塩基対形成する，請求項２６記載のｓｉＮＡ分子。 27. The siNA molecule of claim 26, wherein 21 nucleotides of the antisense region base pair with the nucleotide sequence of RNA encoded by the TNF gene or a portion thereof. 前記アンチセンス領域を含むフラグメントの５’末端が任意にリン酸基を含む，請求項１２記載のｓｉＮＡ分子。 13. The siNA molecule of claim 12, wherein the 5 'end of the fragment comprising the antisense region optionally comprises a phosphate group. 許容可能な担体または希釈剤中に請求項１記載のｓｉＮＡ分子を含む医薬組成物。 A pharmaceutical composition comprising the siNA molecule of claim 1 in an acceptable carrier or diluent.
JP2003569790A 2002-02-20 2003-02-20 RNA interference-mediated inhibition of TNF and TNF receptor superfamily gene expression using short interfering nucleic acids (siNA) Pending JP2005517433A (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US35858002P 2002-02-20 2002-02-20
US36312402P 2002-03-11 2002-03-11
US38678202P 2002-06-06 2002-06-06
US40678402P 2002-08-29 2002-08-29
US40837802P 2002-09-05 2002-09-05
US40929302P 2002-09-09 2002-09-09
US42935902P 2002-11-26 2002-11-26
US44012903P 2003-01-15 2003-01-15
PCT/US2003/004741 WO2003070897A2 (en) 2002-02-20 2003-02-20 RNA INTERFERENCE MEDIATED INHIBITION OF TNF AND TNF RECEPTOR SUPERFAMILY GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)

Publications (2)

Publication Number Publication Date
JP2005517433A JP2005517433A (en) 2005-06-16
JP2005517433A5 true JP2005517433A5 (en) 2006-03-30

Family

ID=27761726

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003569790A Pending JP2005517433A (en) 2002-02-20 2003-02-20 RNA interference-mediated inhibition of TNF and TNF receptor superfamily gene expression using short interfering nucleic acids (siNA)

Country Status (5)

Country Link
EP (1) EP1478730A4 (en)
JP (1) JP2005517433A (en)
AU (1) AU2003217550A1 (en)
CA (1) CA2477014A1 (en)
WO (1) WO2003070897A2 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001257526B2 (en) 2000-05-04 2007-07-19 Avi Biopharma, Inc. Splice-region antisense composition and method
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US7951935B2 (en) 2002-11-14 2011-05-31 Dharmacon, Inc. siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC)
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US9839649B2 (en) 2002-11-14 2017-12-12 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9879266B2 (en) 2002-11-14 2018-01-30 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US7977471B2 (en) 2002-11-14 2011-07-12 Dharmacon, Inc. siRNA targeting TNFα
US7635770B2 (en) 2002-11-14 2009-12-22 Dharmacon, Inc. siRNA targeting protein kinase N-3 (PKN-3)
US9719094B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting SEC61G
US7612196B2 (en) 2002-11-14 2009-11-03 Dharmacon, Inc. siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
US9719092B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting CNTD2
US10011836B2 (en) 2002-11-14 2018-07-03 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US7619081B2 (en) 2002-11-14 2009-11-17 Dharmacon, Inc. siRNA targeting coatomer protein complex, subunit beta 2 (COPB2)
US8198427B1 (en) 2002-11-14 2012-06-12 Dharmacon, Inc. SiRNA targeting catenin, beta-1 (CTNNB1)
EP2284266B1 (en) 2002-11-14 2013-11-06 Thermo Fisher Scientific Biosciences Inc. siRNA targeting tp53
US7691998B2 (en) 2002-11-14 2010-04-06 Dharmacon, Inc. siRNA targeting nucleoporin 62kDa (Nup62)
US7592442B2 (en) 2002-11-14 2009-09-22 Dharmacon, Inc. siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2)
US9771586B2 (en) 2002-11-14 2017-09-26 Thermo Fisher Scientific Inc. RNAi targeting ZNF205
US20050191653A1 (en) * 2003-11-03 2005-09-01 Freier Susan M. Modulation of SGLT2 expression
WO2005117991A2 (en) * 2004-05-04 2005-12-15 Nastech Pharmaceutical Company Inc. Compositions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
US20060040882A1 (en) * 2004-05-04 2006-02-23 Lishan Chen Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
US7605250B2 (en) 2004-05-12 2009-10-20 Dharmacon, Inc. siRNA targeting cAMP-specific phosphodiesterase 4D
US20060253100A1 (en) 2004-10-22 2006-11-09 Medtronic, Inc. Systems and Methods to Treat Pain Locally
US20060189564A1 (en) * 2004-10-22 2006-08-24 Medtronic, Inc. Methods and sequences to suppress pro-inflamatory cytokine actions locally to treat pain
EP1896586A2 (en) 2005-06-28 2008-03-12 Medtronic, Inc. Methods and sequences to preferentially suppress expression of mutated huntingtin
AU2006287481A1 (en) * 2005-09-08 2007-03-15 Mdrna, Inc. Pharmaceutical compositions for delivery of ribonucleic acid to a cell
EP1942943A2 (en) * 2005-11-04 2008-07-16 Nastech Pharmaceutical Company Inc. Peptide-dicer substrate rna conjugates as delivery vehicles for sirna
US7785834B2 (en) 2005-11-10 2010-08-31 Ercole Biotech, Inc. Soluble TNF receptors and their use in treatment of disease
US8138160B2 (en) * 2006-08-03 2012-03-20 Warsaw Orthopedic, Inc. Reagents, methods and systems to suppress pro-inflammatory cytokines
WO2008109369A2 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting tnf gene expression and uses thereof
CN104278033A (en) 2007-05-01 2015-01-14 桑塔里斯制药公司 Splice Switching Oligomers for TNF Superfamily Receptors and their Use in Treatment of Disease
EP3434259A1 (en) 2007-05-04 2019-01-30 Marina Biotech, Inc. Amino acid lipids and uses thereof
US20090036396A1 (en) * 2007-08-03 2009-02-05 Alcon Research, Ltd. RNAi-RELATED INHIBITION OF TNFalpha SIGNALING PATHWAY FOR TREATMENT OF OCULAR ANGIOGENESIS
WO2009033027A2 (en) 2007-09-05 2009-03-12 Medtronic, Inc. Suppression of scn9a gene expression and/or function for the treatment of pain
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
KR20110071017A (en) 2008-10-16 2011-06-27 마리나 바이오테크, 인크. Processes and compositions for liposomal and efficient delivery of gene silencing therapeutics
WO2010096813A1 (en) 2009-02-23 2010-08-26 New York Blood Center Krüppel-like factors and fat regulation
US20100239632A1 (en) 2009-03-23 2010-09-23 Warsaw Orthopedic, Inc. Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
EP2609198B8 (en) 2010-08-24 2018-03-28 Sirna Therapeutics, Inc. SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
PL226431B1 (en) 2013-08-23 2017-07-31 Inst Biochemii I Biofizyki Polskiej Akademii Nauk Particle miR172 of vegetal origin or its synthetic equivalent, method�for decreasing proliferation of lymphocytes B and application of particle miR173

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0649467B1 (en) * 1992-07-02 1998-09-16 HYBRIDON, Inc. Self-stabilized oligonucleotides as therapeutic agents
JPH08505521A (en) * 1992-11-03 1996-06-18 ジーン・シアーズ・プロプライアタリー・リミテッド TNF-α Ribozyme and Degradation-Resistant mRNA Derivative Linked to TNF-α Ribozyme
US6506569B1 (en) * 1997-05-30 2003-01-14 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR10
US6194151B1 (en) * 1997-09-26 2001-02-27 Millenium Pharmaceuticals, Inc. Molecules of the TNF receptor superfamily and uses therefor
WO1999027086A1 (en) * 1997-11-25 1999-06-03 Brax Group Limited Chimeric antisense oligonucleotides against tnf-alpha and their uses
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6007995A (en) * 1998-06-26 1999-12-28 Isis Pharmaceuticals Inc. Antisense inhibition of TNFR1 expression
DE19956568A1 (en) * 1999-01-30 2000-08-17 Roland Kreutzer Method and medicament for inhibiting the expression of a given gene
ES2728168T3 (en) * 2000-12-01 2019-10-22 Max Planck Gesellschaft Small RNA molecules that mediate RNA interference

Similar Documents

Publication Publication Date Title
JP2005517433A5 (en)
JP2005517432A5 (en)
JP2005517438A5 (en)
JP2006502694A5 (en)
JP2005517427A5 (en)
JP2005517430A5 (en)
JP2005517452A5 (en)
JP2005524393A5 (en)
JP2005517436A5 (en)
Hecker et al. Error analysis of chemically synthesized polynucleotides
JP2008283975A5 (en)
CA2457528A1 (en) Rna interference mediated inhibition of hepatitis c virus (hcv) gene expression using short interfering nucleic acid (sina)
DE69635744T2 (en) Modified nucleic acid probes
JP2005500025A5 (en)
CA2526831A1 (en) Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina)
JP2007529224A5 (en)
JP2013535212A5 (en)
JP2009060893A5 (en)
JP2010503382A5 (en)
JP2005518803A5 (en)
SI2287305T2 (en) RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
WO2004007718A3 (en) Rna-interference by single-stranded rna molecules
WO2003040366A3 (en) Inhibitor oligonucleotides and their use for specific repression of a gene
WO2006045590A3 (en) Multidomain rna molecules comprising at least one aptamer for delivering double stranded rna to pest organisms
JP2010512747A5 (en)